CoChat

A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers

Tatosian, Daniel A., Shuler, Michael L. · 2009 · Biotechnology and Bioengineering
Cited by 149

The DOI matches its Crossref record.

Abstract

Multidrug resistant (MDR) cancer is difficult to treat. Chemicals that are effective MDR modulators have never exited clinical trials as FDA approved products due to side effects. It has been hypothesized that using a combination of chemotherapeutics with a mixture of MDR modulators (each with different side effects) may lead to useful treatment strategies. Because the experimental space for combination treatments can be large, this space may be impracticable to explore using animal studies. Here we describe an in vitro system based on microfabrication and cell culture that can potentially be used to explore large experimental spaces efficiently. The Microscale Cell Culture Analog (µCCA) concept mimics the body's response using interconnected compartments that represent various tissues or organs. A µCCA is based on the structure of an appropriate physiologically based pharmacokinetic (PBPK) model and emulates the body's dynamic response to exposure to various drugs and chemicals. For this problem we have chosen a µCCA with living cells representing the liver (HepG2/C3A), bone marrow (MEG‐01), uterine cancer (MES‐SA), and a MDR variant of uterine cancer (MES‐SA/DX‐5). In proof of concept experiments we found in 24 h “acute” exposures and 72 h treatments that the µCCA system predicts combining the chemotherapeutic, doxorubicin, with cyclosporine and nicardipine, as MDR modulators will have greater efficacy than using doxorubicin by itself or with either modulator alone. This combined strategy is selective in inhibiting MES‐SA/DX‐5 cell proliferation and may prove to be advantageous in vivo by specifically targeting MDR cancer with acceptable side‐effects. This cell specific synergy was not observed in traditional 96‐well plate assays. By combining the µCCA with a PBPK model, appropriate drug doses and area under the curve exposure for in vivo trials can be extrapolated directly from the results obtained with this device. This device and approach should be useful in screening potential drug/modulator combinations to determine candidate treatments for MDR cancer. Indeed this approach may be useful for in vitro evaluation of human response to a wide range of exposures to mixtures of chemicals or drugs. Biotechnol. Bioeng. 2009;103: 187–198. © 2008 Wiley Periodicals, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/bit.22219

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Tatosian, D. A., & Shuler, M. L.
Venue
Biotechnology and Bioengineering
Publisher
Wiley
Published
2009-01-09
Volume
103
Issue
1
Pages
187-198
ISSN
  • 0006-3592 (ISSN-L)
  • 1097-0290
OpenAlex
W2022941161
Cited by
149
References
0
FWCI
3.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.